Overview:

Summary

GlobalData, the industry analysis specialist, has released its new report, “Chronic Myelogenous Leukemia (CML) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Chronic Myelogenous Leukemia (CML) Therapeutics market. The report identifies the key trends shaping and driving the global Chronic Myelogenous Leukemia (CML) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Chronic Myelogenous Leukemia (CML) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Chronic Myelogenous Leukemia (CML) Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Chronic Myelogenous Leukemia (CML) Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Chronic Myelogenous Leukemia (CML) Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Chronic Myelogenous Leukemia (CML) Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Chronic Myelogenous Leukemia (CML) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Chronic Myelogenous Leukemia (CML) Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Chronic Myelogenous Leukemia (CML) Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Chronic Myelogenous Leukemia (CML) Therapeutics market landscape? – Identify, understand and capitalize."

Companies Mentioned

Novartis AG
Bristol-Myers Squibb
ChemGenex
Pfizer Inc.

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Chronic Myelogenous Leukemia (CML) Therapeutics: Introduction 7
2.1 Overview 7
2.2 Epidemiology 8
2.3 Symptoms 8
2.4 Etiology 9
2.5 Staging of CML 10
2.6 Risk factors for CML 10
2.7 Diagnosis 11
2.7.1 Lab tests for the diagnosis of patients with CML 11
2.7.2 Genetic Tests: 12
2.8 Treatment of CML 13
2.8.1 Targeted Therapy 13
2.8.2 Chemotherapy 13
2.8.3 Surgery 13
2.8.4 Biologic therapy 13
2.8.5 High-dose chemotherapy with stem cell transplant 13
2.8.6 Donor lymphocyte infusion 13
2.8.7 Treatment of CML Patients by Different Phases 14
2.8.8 Treatment Options on the Basis of Line of Treatment 15
2.9 GlobalData Pipeline Report Guidance 16
3 Chronic Myelogenous Leukemia (CML) Therapeutics: Market Characterization 17
3.1 CML Therapeutics Market Size (2005-2010) – Global 17
3.2 CML Therapeutics Market Forecast (2010-2017) – Global 18
3.3 CML Therapeutics Market Size (2005-2010) – The US 19
3.4 CML Therapeutics Market Forecast (2010-2017) – The US 20
3.5 CML Therapeutics Market Size (2005-2010) – France 21
3.6 CML Therapeutics Market Forecast (2010-2017) – France 22
3.7 CML Therapeutics Market Size (2005-2010) – Germany 23
3.8 CML Therapeutics Market Forecast (2010-2017) – Germany 24
3.9 CML Therapeutics Market Size (2005-2010) – Italy 25
3.10 CML Therapeutics Market Forecast (2010-2017) – Italy 26
3.11 CML Therapeutics Market Size (2005-2010) – Spain 27
3.12 CML Therapeutics Market Forecast (2010-2017) – Spain 28
3.13 CML Therapeutics Market Size (2005-2010) – The UK 29
3.14 CML Therapeutics Market Forecast (2010-2017) – The UK 30
3.15 CML Therapeutics Market Size (2005-2010) – Japan 31
3.16 CML Therapeutics Market Forecast (2010-2017) – Japan 32
3.17 Drivers and Barriers for the CML Therapeutics Market 33
3.17.1 Drivers for the CML Therapeutics Market 33
3.17.2 Barriers for the CML Therapeutics Market 34
3.18 Opportunity and Unmet Need Analysis 34
3.19 Key Takeaway 35
4 Chronic Myelogenous Leukemia (CML) Therapeutics: Competitive Assessment 36
4.1 Overview 36
4.2 Strategic Competitor Assessment 36
4.3 Product Profiles for the Major Marketed Products in the CML Therapeutics Market 37
4.3.1 Gleevec (imatinib mesylate) 37
4.3.2 Sprycel (dasatinib) 38
4.3.3 Tasigna (nilotinib) 39
4.4 Key Takeaway 40
5 Chronic Myelogenous Leukemia (CML) Therapeutics: Pipeline Assessment 41
5.1 Overview 41
5.2 Strategic Pipeline Assessment 41
5.3 CML Therapeutics Pipeline – Pipeline by Phases of Development 41
5.3.1 CML Therapeutics – Filed 41
5.3.2 CML Therapeutics – Phase III Pipeline 42
5.3.3 CML Therapeutics – Phase II Pipeline 42
5.3.4 CML Therapeutics – Phase I Pipeline 42
5.3.5 CML Therapeutics – Pre-clinical and Discovery Pipeline 43
5.3.6 Technology Trends Analytic Framework 43
5.4 CML Therapeutics – Pipeline by Mechanism of Action 45
5.5 Molecule Profile for Promising Drugs Under Clinical Development 46
5.5.1 Omapro (omacetaxine mepesuccinate) 46
5.5.2 Bosutinib (SKI-606) 46
6 Chronic Myelogenous Leukemia (CML) Therapeutics: Clinical Trials Mapping 48
6.1 Clinical Trials by Country (US, EU5 and Japan) 48
6.2 Clinical Trials by Phase 49
6.3 Clinical Trials by Trial Status 50
6.4 Prominent Sponsors 51
6.5 Top Companies Participating in CML Therapeutics Clinical Trials 53
7 Chronic Myelogenous Leukemia (CML) Therapeutics: Strategic Assessment 54
7.1 Key Events Impacting the Future Market 54
7.2 CML Therapeutics: Implications for Future Market Competition 55
8 Chronic Myelogenous Leukemia (CML) Therapeutics: Future Players 56
8.1 Introduction 56
8.2 Company Profiles 56
8.2.1 Novartis AG 56
8.2.2 Bristol-Myers Squibb 61
8.2.3 ChemGenex 63
8.2.4 Pfizer Inc. 64
8.2.5 Other Companies in the CML Therapeutics Market 70
9 Chronic Myelogenous Leukemia (CML) Therapeutics: Licensing and Partnership Deals 72
10 CML Therapeutics: Appendix 80
10.1 Market Definitions 80
10.2 Abbreviations 80
10.3 Methodology 81
10.3.1 Coverage 81
10.3.2 Secondary Research 82
10.3.3 Forecasting 82
10.3.4 Primary Research 84
10.3.5 Expert Panel Validation 85
10.4 Contact Us 85
10.5 Disclaimer 85
10.6 Bibliography 85"

1.1 List of Tables
Table 1: CML Incidence by Age Group, 2004-2008 8
Table 2: CML Therapeutics Market, Global, Revenue ($m), 2005–2010 17
Table 3: CML Therapeutics Market, Global, Forecast ($m), 2010–2017 18
Table 4: CML Therapeutics Market, The US, Revenue ($m), 2005–2010 19
Table 5: CML Therapeutics Market, The US, Forecast ($m), 2010–2017 20
Table 6: CML Therapeutics Market, France, Revenue ($m), 2005–2010 21
Table 7: CML Therapeutics Market, France, Forecast ($m), 2010–2017 22
Table 8: CML Therapeutics Market, Germany, Revenue ($m), 2005–2010 23
Table 9: CML Therapeutics Market, Germany, Forecast ($m), 2010–2017 24
Table 10: CML Therapeutics Market, Italy, Revenue ($m), 2005–2010 25
Table 11: CML Therapeutics Market, Italy, Forecast ($m), 2010–2017 26
Table 12: CML Therapeutics Market, Spain, Revenue ($m), 2005–2010 27
Table 13: CML Therapeutics Market, Spain, Forecast ($m), 2010–2017 28
Table 14: CML Therapeutics Market, The UK, Revenue ($m), 2005–2010 29
Table 15: CML Therapeutics Market, The UK, Forecast ($m), 2010–2017 30
Table 16: CML Therapeutics Market, Japan, Revenue ($m), 2005–2010 31
Table 17: CML Therapeutics Market, Japan, Forecast ($m), 2010–2017 32
Table 18: CML Therapeutics – Filed Pipeline, 2011 41
Table 19: CML Therapeutics – Phase III Pipeline, 2011 42
Table 20: CML Therapeutics – Phase II Pipeline, 2011 42
Table 21: CML Therapeutics – Phase I Pipeline, 2011 42
Table 22: CML Therapeutics – Pre-clinical and Discovery Pipeline, 2011 43
Table 23: CML Therapeutics – Clinical Trials by Country, 2011 48
Table 24: CML Therapeutics – Clinical Trials by Phase, 2011 49
Table 25: CML Therapeutics – Clinical Trials by Status, 2011 50
Table 26: CML Therapeutics – Prominent Sponsors, 2011 52
Table 27: CML Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 53
Table 28: Novartis Deals, 2009-2010 58
Table 29: Bristol Myers Squibb, Deals, 2009-2010 62
Table 30: ChemGenex Inc. – Oncology, Pipeline, 2010 63
Table 31: ChemGenex Inc. – CML, Pipeline, 2010 64
Table 32: ChemGenex Deals, 2010 64
Table 33: Pfizer Inc. – Oncology, Pipeline, 2010 66
Table 34: Pfizer Inc. – CML, Pipeline, 2010 67
Table 35: Pfizer Deals, 2009-2010 67
Table 36: CML Therapeutics Market – Future Players 70
Table 37: CML Therapeutics, Global, Deals 72"

1.2 List of Figures
Figure 1:    Hematopoisis, Blood Stem Cell Goes Through Several Steps to Become a RBC, WBC and Platelet 7
Figure 2: Formation of Philadelphia (Ph) chromosome 9
Figure 3: Staging of CML 10
Figure 4: Bone Marrow Aspiration and Biopsy 11
Figure 5: Testing for CML 12
Figure 6: CML Therapeutics Market, Global, Revenue ($m), 2005–2010 17
Figure 7: CML Therapeutics Market, Global, Forecast ($m), 2010–2017 18
Figure 8: CML Therapeutics Market, the US, Revenue ($m), 2005–2010 19
Figure 9: CML Therapeutics Market, The US, Forecast ($m), 2010–2017 20
Figure 10: CML Therapeutics Market, France, Revenue ($m), 2005–2010 21
Figure 11: CML Therapeutics Market, France, Forecast ($m), 2010–2017 22
Figure 12: CML Therapeutics Market, Germany, Revenue ($m), 2005–2010 23
Figure 13: CML Therapeutics Market, Germany, Forecast ($m), 2010–2017 24
Figure 14: CML Therapeutics Market, Italy, Revenue ($m), 2005–2010 25
Figure 15: CML Therapeutics Market, Italy, Forecast ($m), 2010–2017 26
Figure 16: CML Therapeutics Market, Spain, Revenue ($m), 2005–2010 27
Figure 17: CML Therapeutics Market, Spain, Forecast ($m), 2010–2017 28
Figure 18: CML Therapeutics Market, The UK, Revenue ($m), 2005–2010 29
Figure 19: CML Therapeutics Market, The UK, Forecast ($m), 2010–2017 30
Figure 20: CML Therapeutics Market, Japan, Revenue ($m), 2005–2010 31
Figure 21: CML Therapeutics Market, Japan, Forecast ($m), 2010–2017 32
Figure 22: Opportunity and Unmet Need in the CML Therapeutics Market 34
Figure 23: CML Therapeutics – Strategic Competitor Assessment, 2010 36
Figure 24: CML Therapeutics – Pipeline by Phase of Development, 2010 41
Figure 25: CML Therapeutics – Technology Trends Analytic Framework, 2011 44
Figure 26: CML Therapeutics – Technology Trends Analytic Framework – Description, 2011 44
Figure 27: CML Therapeutics – Pipeline by Mechanism of Action, 2011 45
Figure 28: CML Therapeutics – Clinical Trials by Country, 2011 48
Figure 29: CML Therapeutics – Clinical Trials by Phase, 2011 49
Figure 30:  CML Therapeutics – Clinical Trials by Status, 2011 50
Figure 31: CML Therapeutics – Overall Sponsors, 2011 51
Figure 32: CML Therapeutics – Prominent Sponsors, 2011 52
Figure 33:  CML Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 53
Figure 34: CML Therapeutics Market, Drivers and Restraints 2010 54
Figure 35: Implications for Future Market Competition in the CML Therapeutics Market, 2010 55
Figure 36: CML Therapeutics Market – Pipeline by Company, 2010 56
Figure 37: GlobalData Market Forecasting Model 84